Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS (clinicaltrials.gov) - Oct 24, 2023 - P1 | N=60 | Not yet recruiting | Sponsor: Shanghai YingLi Pharmaceutical Co. Ltd.
Metastases • New P1 trial • Oncology • Solid Tumor • HRAS • KRAS • NRAS • PD-L1
|